Seventy-four (16.7%) patients had a history of inflammatory articular manifestations before anti-TNF’s initiation: SpA in 37 (8.3%), including 17 (46%) axial, 14 (38%) peripheral and 6 (16%) axial and peripheral SpA, peripheral arthralgia associated with IBD symptoms in 27 (6.1%), and inflammatory manifestations linked to another diagnosis in 10 (2.3%), including eight inflammatory spontaneously regressive arthralgia without specific diagnosis, 1 rheumatoid arthritis and one patient with gout. The gene discussed is TNF; the disease is inflammatory bowel disease.